TGFbR1 ELISA kit (Human)

SKU: SEA397Hu

Size: 96Tests

# of Times Cited in literature: 2

Prepare Time: 2-7 days(please inquire for mutiple units)

Target Name: TGFbR1

Target Full Name: Transforming Growth Factor Beta Receptor I

Alternative Names: ACVRLK4; AAT5; ALK5; SKR4; TGFR-1; Activin A Receptor Type II-Like Kinase 53kDa; Activin receptor-like kinase 5; Serine/threonine-protein kinase receptor R4

Target Species: Human

Uniprot: P36897

Gene ID: 7046

Featured Series: SE kit

Featured Series Function: Detects protein (regular version)

Specificity: Reactive with Human TGFbR1 / Transforming Growth Factor Beta Receptor I

Method: Colormetric

Detection principle: Double-antibody Sandwich

Detection range: 0.312-20ng/mL

Sensitivity: 0.122ng/mL

Assay Time: 3h

Sample Size: 100uL

Recommended/Predicted Sample Types: Tissue Homogenates, Cell Lysates, Cell Culture Supernates and other Biological Fluids

Assay Precision: Intra-Assay: CV<10%, Inter-Assay: CV<12%

Reproducibility test menthod: Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Transforming Growth Factor Beta Receptor I (TGFbR1) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Transforming Growth Factor Beta Receptor I (TGFbR1) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100

Storage: 4°C for 1 month/ -20°C for long-term(One year within shelf life)

Shelf-life: 12 months

Specificity: This assay has high sensitivity and excellent specificity for detection of Transforming Growth Factor Beta Receptor I (TGFbR1). No significant cross-reactivity or interference between Transforming Growth Factor Beta Receptor I (TGFbR1) and analogues was observed.

Stability: The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Assay procedure summary: 1. Prepare all reagents, samples and standards; 2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C; 3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C; 4. Aspirate and wash 3 times; 5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C; 6. Aspirate and wash 5 times; 7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C; 8. Add 50µL Stop Solution. Read at 450nm immediately.

Test principle: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Transforming Growth Factor Beta Receptor I (TGFbR1). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Transforming Growth Factor Beta Receptor I (TGFbR1). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Transforming Growth Factor Beta Receptor I (TGFbR1), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Transforming Growth Factor Beta Receptor I (TGFbR1) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

Research Area: Tumor immunity;Infection immunity;

References Citing This Product: Gallium, a promising candidate to disrupt the vicious cycle driving osteolytic metastases.

TGF-β/BAMBI pathway dysfunction contributes to peripheral Th17/Treg imbalance in chronic obstructive pulmonary disease.

Multiple soluble TGF-β receptors in addition to soluble endoglin are elevated in preeclamptic serum and they synergistically inhibit TGF-β signalling